Clinical prediction rule for RSV bronchiolitis in healthy newborns: Prognostic birth cohort study

Pediatrics

Volumn 127, Issue 1, 2011, Pages 35-41

  Houben, Michiel L ^a   Bont, Louis ^a   Wilbrink, Berry ^b   Belderbos, Mirjam E ^a   Kimpen, Jan L L ^a   Visser, Gerard H A ^c   Rovers, Maroeska M ^c  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b NATIONAL INSTITUTE FOR PUBLIC HEALTH AND THE ENVIRONMENT   (Netherlands)

^c UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

Birth cohort study; Health related quality of life; Lower respiratory tract infection; Postbronchiolitis wheeze; Respiratory syncytial virus; Risk stratification

Indexed keywords

ARTICLE; BIRTH WEIGHT; CHILD; CONTROLLED STUDY; COUGHING; DISEASE SEVERITY; FEMALE; HUMAN; INFANT; LOWER RESPIRATORY TRACT INFECTION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NETHERLANDS; NEWBORN; NEWBORN MONITORING; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROGNOSIS; RESPIRATORY SYNCYTIAL PNEUMOVIRUS; RESPIRATORY SYNCYTIAL VIRUS INFECTION; VIRAL BRONCHIOLITIS; WHEEZING;

BRONCHIOLITIS, VIRAL; COHORT STUDIES; FEMALE; FORECASTING; HUMANS; INFANT; INFANT, NEWBORN; MALE; MULTIVARIATE ANALYSIS; REGRESSION ANALYSIS; RESPIRATORY SYNCYTIAL VIRUS INFECTIONS;

EID: 78650763398     PISSN: 00314005     EISSN: 10984275     Source Type: Journal    
DOI: 10.1542/peds.2010-0581     Document Type: Article

References (44)

1. Hall CB, Weinberg GA, Iwane MK, et al. The burden of respiratory syncytial virus infection in young children. N Engl J Med. 2009;360(6):588-598
2. Bourgeois FT, Valim C, McAdam AJ, Mandl KD. Relative impact of influenza and respiratory syncytial virus in young children. Pediatrics. 2009;124(6). Available at: www.pediatrics.org/cgi/content/full/124/6/e1072
3. Stein RT, Sherrill D, Morgan WJ, et al. Respiratory syncytial virus in early life and risk of wheeze and allergy by age 13 years. Lancet. 1999;354(9178):541-545
4. Bont L, Steijn M, Van Aalderen WM, et al. Seasonality of long term wheezing following respiratory syncytial virus lower respiratory tract infection. Thorax. 2004;59(6):512-516 (Pubitemid 38797525)
5. Bont L, Steijn M, Van Aalderen WM, Kimpen JL. Impact of wheezing after respiratory syncytial virus infection on health-related quality of life. Pediatr Infect Dis J. 2004;23(5):414-417 (Pubitemid 38621479)
6. Contreras PA, Sami IR, Darnell ME, Ottolini MG, Prince GA. Inactivation of respiratory syncytial virus by generic hand dishwashing detergents and antibacterial hand soaps. Infect Control Hosp Epidemiol. 1999;20(1):57-58
7. Forbes M. Strategies for preventing respiratory syncytial virus. Am J Health Syst Pharm. 2008;65(23 suppl 8):S13-S19
8. Jafri HS. Treatment of respiratory syncytial virus: antiviral therapies. Pediatr Infect Dis J. 2003;22(2 suppl):S89-S92
9. van de Pol AC, Rossen JW, Wolfs TF, et al. Transmission of respiratory syncytial virus at the paediatric intensive-care unit: a prospective study using real-time PCR. Clin Microbiol Infect. 2010;16(5):488-490
10. IMpact-RSV Study Group. Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. Pediatrics. 1998;102(3):531-537
11. Ramilo O. Evolution of prophylaxis: MoAb, siRNA, vaccine, and small molecules. Paediatr Respir Rev. 2009;10(suppl 1):23-25
12. Bloemers BLP, van Furth AM, Weijerman ME, et al. Down syndrome: a novel risk factor for respiratory syncytial virus bronchiolitis: a prospective birth-cohort study. Pediatrics. 2007;120(4). Available at: www.pediatrics.org/ cgi/content/full/120/4/e1076
13. Simoes EA. Environmental and demographic risk factors for respiratory syncytial virus lower respiratory tract disease. J Pediatr. 2003;143(5 suppl):S118-S126
14. Doering G, Gusenleitner W, Belohradsky BH, Burdach S, Resch B, Liese JG. The risk of respiratory syncytial virus-related hospitalizations in preterm infants of 29 to 35 weeks' gestational age. Pediatr Infect Dis J. 2006;25(12):1188-1190
15. Feltes TF, Cabalka AK, Meissner HC, et al. Palivizumab prophylaxis reduces hospitalization due to respiratory syncytial virus in young children with hemodynamically significant congenital heart disease. J Pediatr. 2003;143(4):532-540
16. Hall CB. Respiratory syncytial virus and parainfluenza virus. N Engl J Med. 2001;344(25):1917-1928
17. Holberg CJ, Wright AL, Martinez FD, Ray CG, Taussig LM, Lebowitz MD. Risk factors for respiratory syncytial virus-associated lower respiratory illnesses in the first year of life. Am J Epidemiol. 1991;133(11):1135-1151
18. Nachman SA, Navaie-Waliser M, Qureshi MZ. Rehospitalization with respiratory syncytial virus after neonatal intensive care unit discharge: a 3-year follow-up. Pediatrics. 1997;100(6). Available at: www.pediatrics.org/cgi/ content/full/100/6/e8
19. Shay DK, Holman RC, Newman RD, Liu LL, Stout JW, Anderson LJ. Bronchiolitis-associated hospitalizations among US children, 1980-1996. JAMA. 1999;282(15):1440-1446
20. Stevens TP, Sinkin RA, Hall CB, Maniscalco WM, McConnochie KM. Respiratory syncytial virus and premature infants born at 32 weeks' gestation or earlier: hospitalization and economic implications of prophylaxis. Arch Pediatr Adolesc Med. 2000;154(1):55-61
21. Simões EA, Carbonell-Estrany X, Fullarton JR, et al. A predictive model for respiratory syncytial virus (RSV) hospitalisation of premature infants born at 33-35 weeks of gestational age, based on data from the Spanish FLIP study. Respir Res. 2008;9(1):78
22. Rietveld E, Vergouwe Y, Steyerberg EW, Huysman MW, de Groot R, Moll HA. Hospitalization for respiratory syncytial virus infection in young children: development of a clinical prediction rule. Pediatr Infect Dis J. 2006;25(3):201-207
23. Law BJ, Langley JM, Allen U, et al. The Pediatric Investigators Collaborative Network on Infections in Canada study of predictors of hospitalization for respiratory syncytial virus infection for infants born at 33 through 35 completed weeks of gestation. Pediatr Infect Dis J. 2004;23(9):806-814 (Pubitemid 40221021)
24. Landon MB, Spong CY, Thom E, et al. A multicenter, randomized trial of treatment for mild gestational diabetes. N Engl J Med. 2009;361(14):1339-1348
25. Ochola R, Sande C, Fegan G, et al. The level and duration of RSV-specific maternal IgG in infants in Kilifi, Kenya. PLoS One. 2009;4(12):e8088
26. Ermers MJ, Rovers MM, van Woensel JB, Kimpen JL, Bont LJ. The effect of high dose inhaled corticosteroids on wheeze in infants after respiratory syncytial virus infection: randomised double blind placebo controlled trial. BMJ. 2009;338:b897
27. van der Zalm MM, van Ewijk BE, Wilbrink B, Uiterwaal CS, Wolfs TF, van der Ent CK. Respiratory pathogens in children with and without respiratory symptoms. J Pediatr. 2009;154(3):396-400
28. Brunekreef B, Groot B, Rijcken B, Hoek G, Steenbekkers A, de Boer A. Reproducibility of childhood respiratory symptom questions. Eur Respir J. 1992;5(8):930-935
29. Fekkes M, Theunissen NC, Brugman E, et al. Development and psychometric evaluation of the TAPQOL: a health-related quality of life instrument for 1-5-year-old children. Qual Life Res. 2000;9(8):961-972
30. Theunissen NC, Veen S, Fekkes M, et al. Quality of life in preschool children born preterm. Dev Med Child Neurol. 2001;43(7):460-465
31. Royston P, Moons KG, Altman DG, Vergouwe Y. Prognosis and prognostic research: developing a prognostic model. BMJ. 2009;338:b604
32. Altman DG, Vergouwe Y, Royston P, Moons KG. Prognosis and prognostic research: validating a prognostic model. BMJ. 2009;338:b605
33. Harrell FE Jr, Lee KL, Mark DB. Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. Stat Med. 1996;15(4):361-387
34. Atègbo JM, Grissa O, Yessoufou A, et al. Modulation of adipokines and cytokines in gestational diabetes and macrosomia. J Clin Endocrinol Metab. 2006;91(10):4137-4143 (Pubitemid 44536897)
35. Moore TR. A comparison of amniotic fluid fetal pulmonary phospholipids in normal and diabetic pregnancy. Am J Obstet Gynecol. 2002;186(4):641-650
36. Saunders NR, Tennis O, Jacobson S, Gans M, Dick PT. Parents' responses to symptoms of respiratory tract infection in their children. CMAJ. 2003;168(1):25-30
37. de Jong BM, van der Ent CK, van der Zalm MM, et al. Respiratory symptoms in young infancy: child, parent and physician related determinants of drug prescription in primary care. Pharmacoepidemiol Drug Saf. 2009;18(7):610-618
38. Zwart JJ, Richters JM, Ory F, de Vries JI, Bloemenkamp KW, van Roosmalen J. Severe maternal morbidity during pregnancy, delivery and puerperium in the Netherlands: a nationwide population-based study of 371,000 pregnancies. BJOG. 2008;115(7):842-850
39. Sterne JA, White IR, Carlin JB, et al. Multiple imputation for missing data in epidemiological and clinical research: potential and pitfalls. BMJ. 2009;338:b2393
40. Greenland S, Finkle WD. A critical look at methods for handling missing covariates in epidemiologic regression analyses. Am J Epidemiol. 1995;142(12):1255-1264 (Pubitemid 26006424)
41. Olszewska W, Openshaw P. Emerging drugs for respiratory syncytial virus infection. Expert Opin Emerg Drugs. 2009;14(2):207-217
42. DeVincenzo J, Cehelsky JE, Alvarez R, et al. Evaluation of the safety, tolerability and pharmacokinetics of ALN-RSV01, a novel RNAi antiviral therapeutic directed against respiratory syncytial virus (RSV). Antiviral Res. 2008;77(3):225-231
43. DeVincenzo J, Lambkin-Williams R, Wilkinson T, et al. A randomized, double-blind, placebo-controlled study of an RNAi-based therapy directed against respiratory syncytial virus. Proc Natl Acad Sci U S A. 2010;107(19):8800-8805
44. Empey KM, Peebles RS Jr, Kolls JK. Pharmacologic advances in the treatment and prevention of respiratory syncytial virus. Clin Infect Dis. 2010;50(9):1258-1267